Eli Lilly and Company (LLY) Major Shareholder Sells $15,680,700.00 in Stock

Eli Lilly and Company (NYSE:LLY) major shareholder Lilly Endowment Inc sold 190,000 shares of Eli Lilly and stock in a transaction dated Friday, September 15th. The stock was sold at an average price of $82.53, for a total value of $15,680,700.00. Following the transaction, the insider now owns 123,682,287 shares in the company, valued at $10,207,499,146.11. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Lilly Endowment Inc also recently made the following trade(s):

  • On Thursday, August 31st, Lilly Endowment Inc sold 180,000 shares of Eli Lilly and stock. The stock was sold at an average price of $81.06, for a total value of $14,590,800.00.
  • On Monday, July 31st, Lilly Endowment Inc sold 220,000 shares of Eli Lilly and stock. The stock was sold at an average price of $83.09, for a total value of $18,279,800.00.
  • On Thursday, June 22nd, Lilly Endowment Inc sold 210,000 shares of Eli Lilly and stock. The stock was sold at an average price of $84.43, for a total value of $17,730,300.00.
  • On Tuesday, June 20th, Lilly Endowment Inc sold 215,000 shares of Eli Lilly and stock. The stock was sold at an average price of $83.05, for a total value of $17,855,750.00.

Shares of Eli Lilly and Company (NYSE:LLY) opened at 82.02 on Thursday. The company has a market cap of $86.53 billion, a price-to-earnings ratio of 35.49 and a beta of 0.34. Eli Lilly and Company has a 12-month low of $64.18 and a 12-month high of $86.72. The company’s 50-day moving average price is $80.84 and its 200 day moving average price is $82.02.

Eli Lilly and (NYSE:LLY) last announced its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.05 by $0.06. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The business had revenue of $5.82 billion for the quarter, compared to analysts’ expectations of $5.60 billion. During the same quarter last year, the firm earned $0.86 EPS. The firm’s revenue for the quarter was up 7.8% compared to the same quarter last year. Equities analysts predict that Eli Lilly and Company will post $4.16 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This report was first reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this report on another site, it was copied illegally and reposted in violation of United States & international trademark & copyright laws. The correct version of this report can be viewed at https://www.chaffeybreeze.com/2017/09/21/eli-lilly-and-company-lly-major-shareholder-sells-15680700-00-in-stock.html.

A number of hedge funds and other institutional investors have recently made changes to their positions in LLY. Acrospire Investment Management LLC lifted its position in Eli Lilly and by 16.7% in the 2nd quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock valued at $115,000 after acquiring an additional 200 shares in the last quarter. MPS Loria Financial Planners LLC bought a new position in Eli Lilly and in the 2nd quarter valued at about $128,000. San Francisco Sentry Investment Group CA bought a new position in Eli Lilly and in the 2nd quarter valued at about $129,000. Heritage Trust Co bought a new position in Eli Lilly and in the 1st quarter valued at about $135,000. Finally, Point72 Asia Hong Kong Ltd lifted its position in Eli Lilly and by 237.4% in the 1st quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock valued at $148,000 after acquiring an additional 1,239 shares in the last quarter. 75.72% of the stock is currently owned by institutional investors and hedge funds.

Several research analysts have weighed in on the company. BidaskClub upgraded Eli Lilly and from a “sell” rating to a “hold” rating in a report on Wednesday, June 14th. Barclays PLC lifted their target price on Eli Lilly and from $85.00 to $90.00 and gave the stock an “overweight” rating in a report on Tuesday, July 4th. BMO Capital Markets reiterated a “sell” rating and set a $73.00 target price on shares of Eli Lilly and in a report on Friday, August 4th. Berenberg Bank reiterated a “buy” rating and set a $100.00 target price on shares of Eli Lilly and in a report on Thursday, July 27th. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $96.00 target price (up from $93.00) on shares of Eli Lilly and in a report on Thursday, July 13th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $88.27.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Insider Buying and Selling by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply